@jamecancerdoc@ASCO@OncoAlert Lets take a step back before comparing it to imatinib… perhaps only ATRA deserves to share that podium.
But otherwise fantastic results and hope for mPDAC patients!
@dgermain21@Papa_Heme I agree that there are diffferent levels of review articles and learning has to be multifaceted.. but for example the last review article Eli Estey did in AML was excellent.
@dgermain21@Papa_Heme For fellows? Good review articles are highly valuable… as they can bring a great overview about a disease state. Its different for day to day practice.
@Papa_Heme This is crazy… If any of these patient gets a t-MN will the investigators feel any guilt? I guess when you have enough funding you can just do any trial..
@AhmadRehanKhan Interestingly she doesn’t share that the only studies looking at outcomes of patients treated by IMGs vs US grads shows either equal outcomes or slightly better in the IMGs group. Realistically speaking outcomes are likely equal.